News and Events
IPAC Inhaler Return Campaign (UK)
(Beginning 26 July 2021)
Encourage patients who have an inhaler that is no longer needed or no longer functional to return it to any local pharmacy
Highlight the impact of certain inhaled therapies on the environment
In coordination with the PSNC, BLF and Asthma UK, IPAC developed eight visual designs to be shared across social media in order to raise awareness of the impact of inhaled devices on the environment and of the existing infrastructure to dispose of inhaler’s that are no longer needed or usable.
Who We Are
IPAC was formed almost three decades ago in response to the phase out of CFCs in critical inhalation products under the mandate of the Montreal Protocol on Substances that Deplete the Ozone Layer. IPAC is the premier organization on inhaled products and environmental policy issues and serves as a resource for policymakers and regulators around the world. IPAC’s members research, develop and manufacture metered dose inahlers (MDIs) for the treatment of respiratory illnesses, such as asthma and chronic obstructive pulmonary disease.
With the transition away from CFC MDIs successfully completed, IPAC is focused on preserving the long-term availability of pharmaceutical-grade HFCs – the environmental solution to CFCs in MDIs – for patient use. IPAC closely monitors legislative and policy developments on HFCs and climate change and engages regulators and policymakers on the critical patient care aspects of HFC MDIs.
IPAC recommends that any phase down of HFCs is structured to ensure that adequate, safe, and secure supplies of HFCs remain available to meet patient need over the long term.
"Any consideration of policy measures to control HFCs should carefully assess patient health implications with the goals of ensuring patient health and maintaining a range of therapeutic options."
Protecting Patients and Preserving the Environment:
A Global Accomplishment
IPAC congratulates the Parties to the Montreal Protocol on the completion of the transition away from CFC Metered Dose Inhalers (MDIs) and welcomes the Ozone Secretariat’s announcement that CFC MDIs will disappear completely by end of 2016. This is an impressive achievement. IPAC commends the Parties and the Medical Technical Options Committee on their diligence and commitment in managing this important process over close to three decades.
IPAC commends the Parties to the Montreal Protocol for achieving consensus in Kigali, Rwanda on a path forward for HFCs. Importantly, the Kigali Amendment is a phase down approach recognizing the need to ensure HFCs remain available for MDIs and other sectors where cost-effective and technically feasible alternatives are not available.